Localized gastrointestinal stromal tumor management
Localized small-intestine gastrointestinal stromal tumor (GIST) is treated with complete surgical excision with the aim of achieving negative margins. [1] If surgical excision with R0 margins is not feasible without major functional sequelae, preoperative (neoadjuvant) imatinib is recommended to enable later surgery. [1] Adjuvant imatinib for 3 years is recommended for patients with significant risk of relapse after complete resection. [1]
Medication selection algorithm
Targeted therapy is selected based on molecular findings of the tumor (KIT and PDGFRA) after pathology confirmation. [1]
- Imatinib (initial targeted therapy for imatinib-sensitive disease, including most KIT-mutant and PDGFRA-non–D842V tumors) [1]
- Avapritinib (for PDGFRA exon 18 mutations, including PDGFRA D842V) [1]
- Adjuvant imatinib is avoided for PDGFRA D842V–mutated GIST. [1]
- Adjuvant therapy is avoided in NF1-related and SDH expression–negative GIST. [1]
Key evidence supporting treatment
Adjuvant imatinib for 3 years is the standard approach for patients with significant relapse risk after resection. [1]
Monotherapy versus combination therapy
Surgery plus single-agent tyrosine kinase inhibitor therapy is used in the localized setting. [1] No guideline-supported multi-agent systemic regimen is recommended as routine adjuvant therapy for resected localized GIST. [1]
Treatment initiation thresholds and indications
Adjuvant imatinib is recommended when the risk of relapse is significant based on post-resection risk assessment. [1] Preoperative imatinib is standard when R0 resection implies major functional sequelae and preoperative medical treatment is effective. [1] Neoadjuvant imatinib is also used for very large or poorly positioned primaries that are unresectable without major morbidity, typically continuing until surgical therapy becomes feasible. [2]
Target blood pressure / treatment goals
Treatment goals in localized GIST are durable local control after complete excision and reduction of relapse risk with appropriately selected adjuvant targeted therapy. [1]
Common pitfalls to avoid
- Performing negative-node dissection is not recommended for clinically negative nodes in localized GIST. [1]
- Using adjuvant imatinib for PDGFRA D842V–mutated GIST is not recommended. [1]
- Using adjuvant therapy in NF1-related or SDH expression–negative GIST is not recommended. [1]
Application to dedifferentiated GIST arising de novo
Dedifferentiated histology does not replace the need for standard GIST-directed management. [1] Management should follow the localized GIST framework with molecular profiling and risk-adapted use of perioperative imatinib or alternative targeted therapy based on genotype. [1] Surgical resection with negative margins remains the primary treatment when resectable. [1] Imatinib is used perioperatively when the tumor is expected to be imatinib-sensitive based on KIT/PDGFRA findings, with adjuvant duration and eligibility determined by post-resection relapse risk and genotype. [1]
Clinical follow-up after treatment
Post-resection surveillance is performed after surgery and completion of perioperative targeted therapy consistent with guideline-based follow-up strategies for GIST. [1]